Status:
COMPLETED
Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children
Lead Sponsor:
Novartis Vaccines
Conditions:
Haemophilus Influenzae Type B Infection
Eligibility:
All Genders
2-5 years
Phase:
PHASE4
Brief Summary
This is a multicenter, post marketing surveillance study which aims to evaluate the safety profile of haemophilus influenza type b vaccine when administered to Korean children according to the product...
Eligibility Criteria
Inclusion
- Male and female children 2 months to 5 years of age scheduled to receive vaccination
Exclusion
- Contraindications to Vaxem™Hib Korean Prescribing information
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
764 Patients enrolled
Trial Details
Trial ID
NCT01404962
Start Date
August 1 2011
End Date
July 1 2012
Last Update
December 1 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Moon's Pediatrics Clinic
Gyeonggi-do, South Korea, 449-812
2
Wooriai Pediatrics clinic
Incheon, South Korea, 407-818
3
KyungHee University Hospital
Seoul, South Korea, 130-702
4
Hanil General Hospital
Seoul, South Korea, 132-703